MCID: ADR040
MIFTS: 49

Adrenal Gland Pheochromocytoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Adrenal Gland Pheochromocytoma

MalaCards integrated aliases for Adrenal Gland Pheochromocytoma:

Name: Adrenal Gland Pheochromocytoma 12 15 17
Pheochromocytoma 74

Classifications:



External Ids:

Disease Ontology 12 DOID:0050892
UMLS 74 C0031511

Summaries for Adrenal Gland Pheochromocytoma

Disease Ontology : 12 A malignant pheochromocytoma that is characterized by overproduction of adrenaline.

MalaCards based summary : Adrenal Gland Pheochromocytoma, also known as pheochromocytoma, is related to malignant pediatric adrenal gland pheochromocytoma and pheochromocytoma, and has symptoms including tremor, fever and abdominal pain. An important gene associated with Adrenal Gland Pheochromocytoma is SOCS3 (Suppressor Of Cytokine Signaling 3), and among its related pathways/superpathways are Common Cytokine Receptor Gamma-Chain Family Signaling Pathways and Development HGF signaling pathway. The drugs Doxazosin and Phenoxybenzamine have been mentioned in the context of this disorder. Affiliated tissues include adrenal gland, testes and thyroid, and related phenotypes are cardiovascular system and hematopoietic system

Related Diseases for Adrenal Gland Pheochromocytoma

Diseases related to Adrenal Gland Pheochromocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 malignant pediatric adrenal gland pheochromocytoma 12.7
2 pheochromocytoma 11.7
3 adrenal carcinoma 11.3
4 adrenal cortical adenoma 10.0
5 adenoma 10.0
6 respiratory system cancer 9.7 ANXA5 STAT3
7 large intestine cancer 9.5 ANXA5 MTOR STAT3
8 leukemia, acute myeloid 9.5 ANXA5 MTOR STAT3
9 body mass index quantitative trait locus 11 8.9 KCNH2 MTOR NOS3 SOCS3 STAT3

Graphical network of the top 20 diseases related to Adrenal Gland Pheochromocytoma:



Diseases related to Adrenal Gland Pheochromocytoma

Symptoms & Phenotypes for Adrenal Gland Pheochromocytoma

UMLS symptoms related to Adrenal Gland Pheochromocytoma:


tremor, fever, abdominal pain, headache, chest pain

MGI Mouse Phenotypes related to Adrenal Gland Pheochromocytoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.85 BNIP3 KCNH2 MTOR NOS3 SOCS3 STAT3
2 hematopoietic system MP:0005397 9.8 ANXA5 BNIP3 MTOR NOS3 SOCS3 STAT3
3 homeostasis/metabolism MP:0005376 9.73 BNIP3 KCNH2 MTOR NOS3 SOCS3 STAT3
4 adipose tissue MP:0005375 9.71 MTOR NOS3 SOCS3 STAT3
5 muscle MP:0005369 9.55 BNIP3 KCNH2 MTOR NOS3 STAT3
6 normal MP:0002873 9.35 ANXA5 MTOR NOS3 SOCS3 STAT3
7 skeleton MP:0005390 9.02 ANXA5 MTOR NOS3 SOCS3 STAT3

Drugs & Therapeutics for Adrenal Gland Pheochromocytoma

Drugs for Adrenal Gland Pheochromocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 167)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxazosin Approved Phase 4,Phase 3 74191-85-8 3157
2
Phenoxybenzamine Approved Phase 4,Phase 3,Phase 2 59-96-1 4768
3 Adrenergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
4 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
5 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 3
6 Antihypertensive Agents Phase 4,Phase 3,Phase 2
7 Adrenergic alpha-Antagonists Phase 4,Phase 3,Phase 2
8 Vasodilator Agents Phase 4,Phase 3,Phase 2
9 Adrenergic Antagonists Phase 4,Phase 3,Phase 2
10
Somatostatin Approved, Investigational Phase 2, Phase 3,Phase 1 38916-34-6, 51110-01-1 53481605
11
Lenograstim Approved, Investigational Phase 3 135968-09-1
12
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
13
Ifosfamide Approved Phase 3 3778-73-2 3690
14
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
15
Doxil Approved June 1999 Phase 3,Phase 2 31703
16 3-Iodobenzylguanidine Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Radiopharmaceuticals Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
19 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
20 Alkylating Agents Phase 3,Phase 2,Phase 1
21 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
22
Isophosphamide mustard Phase 3 0
23 Topoisomerase Inhibitors Phase 3,Phase 2
24
Indinavir Approved Phase 2 150378-17-9 5362440
25
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
26
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
27
Epinephrine Approved, Vet_approved Phase 2,Not Applicable 51-43-4 5816
28
Racepinephrine Approved Phase 2,Not Applicable 329-65-7 838
29
Carbidopa Approved Phase 2 28860-95-9 34359
30
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
31
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
32
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
33
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
34
Iodine Approved, Investigational Phase 1, Phase 2,Phase 2,Not Applicable,Early Phase 1 7553-56-2 807
35
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 5284616 6436030
36
Everolimus Approved Phase 2,Phase 1 159351-69-6 70789204 6442177
37
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
38
Sodium Citrate Approved, Investigational Phase 2 68-04-2
39
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
40
Tamoxifen Approved Phase 2 10540-29-1 2733526
41
Pancrelipase Approved, Investigational Phase 2,Not Applicable 53608-75-6
42
Melphalan Approved Phase 2 148-82-3 460612 4053
43
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
44
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
45
Octreotide Approved, Investigational Phase 1, Phase 2,Phase 2 83150-76-9 6400441 383414
46
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
47
Lenvatinib Approved, Investigational Phase 2 417716-92-8
48
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
49
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
50
Ipilimumab Approved Phase 2 477202-00-9

Interventional clinical trials:

(show top 50) (show all 94)
# Name Status NCT ID Phase Drugs
1 Phenoxybenzamine Versus Doxazosin in PCC Patients Completed NCT01379898 Phase 4 Phenoxybenzamine;Doxazosin
2 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Completed NCT01959711 Phase 4
3 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
4 Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma Completed NCT00126412 Phase 3 123I-mIBG (meta-iodobenzylguanidine)
5 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
6 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
7 Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors Completed NCT00442533 Phase 2, Phase 3 Indium-111 pentetreotide
8 Preoperative Alpha Blockade for Pheochromocytoma Recruiting NCT03176693 Phase 3 Phenoxybenzamine;Doxazosin
9 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms Unknown status NCT01237457 Phase 2 177Lu-DOTATATE
10 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
11 131MIBG to Treat Malignant Pheochromocytoma Completed NCT00028106 Phase 2 [131]I-MIBG;6-[18F]Fluorodopamine;[123]I-MIBG
12 Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma Completed NCT00458952 Phase 1, Phase 2 Ultratrace Iobenguane (MIBG) I 131
13 A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors Completed NCT01413503 Phase 2
14 RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid Completed NCT01152827 Phase 2 RAD001
15 A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... Completed NCT00923481 Phase 2 Fostamatinib disodium
16 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
17 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
18 Capecitabine and Temozolomide for Neuroendocrine Cancers Completed NCT00869050 Phase 2 Capecitabine;Temozolomide
19 RAD001 and Erlotinib in Patients With Neuroendocrine Tumors Completed NCT00843531 Phase 2 RAD001;erlotinib
20 Phase II Study of Vandetanib in Individuals With Kidney Cancer Completed NCT00566995 Phase 2 ZACTIMA (Vandetanib) (ZD6474)
21 17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease Completed NCT00088374 Phase 2 17 allylamino-17-demethoxygeldanamycin;18 FDG (Fludeoxyglucose 18F);[15-O] H2O;EPL diluent
22 Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma Recruiting NCT03839498 Phase 2 Axitinib
23 Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery Recruiting NCT03008369 Phase 2 Lenvatinib
24 First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma Recruiting NCT01371201 Phase 2 Sunitinib;Placebo
25 Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable Metastatic Pheochromocytomas and Paragangliomas Recruiting NCT02302833 Phase 2 Cabozantinib
26 Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma Recruiting NCT03206060 Phase 2 Lu-177-DOTATATE;Ga-68-DOTATATE;F-18-FDG;Amino Acid solution
27 Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma Recruiting NCT00107289 Phase 2
28 A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer Recruiting NCT03165721 Phase 2 SGI-110 (guadecitabine)
29 Phase 2 Study of ONC201 in Neuroendocrine Tumors Recruiting NCT03034200 Phase 2 ONC201
30 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
31 MIBG Therapy for Patients With MIBG Avid Tumors Recruiting NCT02378428 Phase 2 MIBG
32 Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic Recruiting NCT02721732 Phase 2
33 Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma Active, not recruiting NCT00843037 Phase 2 Sunitinib
34 A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma Active, not recruiting NCT00874614 Phase 2
35 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma Active, not recruiting NCT01967576 Phase 2 Axitinib (AG-013736)
36 Dovitinib in Neuroendocrine Tumors Active, not recruiting NCT01635907 Phase 2 Dovitinib
37 Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors Active, not recruiting NCT01967537 Phase 2 68Gallium DOTATATE
38 LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA) Not yet recruiting NCT03946527 Phase 2 Lanreotide
39 Dosimetry Guided PRRT With 177Lu-DOTATATE in Children Not yet recruiting NCT03923257 Phase 1, Phase 2 177Lu-DOTA-tyr3-OCTREOTATE
40 Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma Terminated NCT01340794 Phase 2 Pazopanib Hydrochloride
41 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
42 Parenteral Phenoxybenzamine During Congenital Heart Disease Surgery Withdrawn NCT00770705 Phase 2 Phenoxybenzamine
43 ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid Completed NCT00339131 Phase 1 Ultratrace iobenguane I 131
44 Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Completed NCT00049023 Phase 1
45 Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
46 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib
47 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
48 Diagnosis of Pheochromocytoma Recruiting NCT00004847 Phase 1 Fluorodopamine;F-18 Fluorodopa
49 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
50 Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma Withdrawn NCT01941849 Phase 1 Vandetanib

Search NIH Clinical Center for Adrenal Gland Pheochromocytoma

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Adrenal Gland Pheochromocytoma

Anatomical Context for Adrenal Gland Pheochromocytoma

MalaCards organs/tissues related to Adrenal Gland Pheochromocytoma:

42
Adrenal Gland, Testes, Thyroid, Heart, Liver, Kidney, Bone

Publications for Adrenal Gland Pheochromocytoma

Articles related to Adrenal Gland Pheochromocytoma:

(show top 50) (show all 2993)
# Title Authors Year
1
Commentary on an Acute Care Surgery Challenge: Abdominal Aortic Aneurysm and Pheochromocytoma. ( 30629010 )
2019
2
Pheochromocytoma-related cardiomyopathy presenting as broken heart syndrome: Case report and literature review. ( 30641325 )
2019
3
Renal infarction associated with extra-adrenal pheochromocytoma. ( 30851287 )
2019
4
Occult extra-adrenal pheochromocytoma in the urinary bladder. ( 30852507 )
2019
5
Thunderclap Headache and Cerebral Vasoconstriction Secondary to Pheochromocytoma. ( 30801609 )
2019
6
Pheochromocytoma presenting with severe hyperglycemia and metabolic acidosis following intra-articular glucocorticoid administration: a case report. ( 30609924 )
2019
7
Incidence and predictive factors of hypoglycemia after pheochromocytoma resection. ( 30467902 )
2019
8
Impact of Extrinsic and Intrinsic Hypoxia on Catecholamine Biosynthesis in Absence or Presence of Hif2α in Pheochromocytoma Cells. ( 31035382 )
2019
9
Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. ( 30715419 )
2019
10
Expression of PDK1 in malignant pheochromocytoma as a new promising potential therapeutic target. ( 30759304 )
2019
11
Prognostic Factors of Malignant Pheochromocytoma and Paraganglioma: A Combined SEER and TCGA Databases Review. ( 30919391 )
2019
12
Correction: Prognostic Factors of Malignant Pheochromocytoma and Paraganglioma: A Combined SEER and TCGA Databases Review. ( 30986868 )
2019
13
Anti-tumor effects and potential therapeutic response biomarkers in α-emitting meta-211At-astato-benzylguanidine therapy for malignant pheochromocytoma explored by RNA-sequencing. ( 31037122 )
2019
14
Preclinical Evaluation of the Acute Radiotoxicity of the α-Emitting Molecular-Targeted Therapeutic Agent 211At-MABG for the Treatment of Malignant Pheochromocytoma in Normal Mice. ( 31078058 )
2019
15
Pheochromocytoma in Children and Adolescents With Multiple Endocrine Neoplasia Type 2B. ( 30113649 )
2019
16
Impact of 123 I-MIBG scintigraphy on clinical decision making in pheochromocytoma and paraganglioma. ( 30822354 )
2019
17
Clinical, Diagnostic, and Treatment Characteristics of SDHA-Related Metastatic Pheochromocytoma and Paraganglioma. ( 30854332 )
2019
18
Targeted next-generation sequencing detects rare genetic events in pheochromocytoma and paraganglioma. ( 30877234 )
2019
19
Metastatic pheochromocytoma and paraganglioma: recent advances in prognosis and management. ( 30893083 )
2019
20
Genotype-phenotype correlations in pheochromocytoma and paraganglioma. ( 30893643 )
2019
21
FGF21 Levels in Pheochromocytoma/Functional Paraganglioma. ( 30959789 )
2019
22
The role of 68Ga-DOTA-Octreotate (GaTate) PET/CT in follow-up of SDH-associated pheochromocytoma and paraganglioma (PPGL). ( 30977831 )
2019
23
A Previously Unrecognized Monocytic Component of Pheochromocytoma and Paraganglioma. ( 31001800 )
2019
24
Blood Pressure Profile, Catecholamine Phenotype and Target Organ Damage in Pheochromocytoma/Paraganglioma. ( 31009053 )
2019
25
Chromogranin A in the Laboratory Diagnosis of Pheochromocytoma and Paraganglioma. ( 31027285 )
2019
26
Analysis of Short-term Blood Pressure Variability in Pheochromocytoma/Paraganglioma Patients. ( 31083609 )
2019
27
SDHx-related pheochromocytoma/paraganglioma - genetic, clinical, and treatment outcomes in a series of 30 patients from a single center. ( 31104306 )
2019
28
A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. ( 31105270 )
2019
29
A phase I clinical trial for [131I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma. ( 31110198 )
2019
30
Performance of 68Ga-DOTA-Conjugated Somatostatin Receptor-Targeting Peptide PET in Detection of Pheochromocytoma and Paraganglioma: A Systematic Review and Metaanalysis. ( 30030341 )
2019
31
Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma. ( 30050099 )
2019
32
Current status of functional imaging in neuroblastoma, pheochromocytoma, and paraganglioma disease. ( 30182289 )
2019
33
Efficacy and Safety of High-Specific-Activity 131I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma. ( 30291194 )
2019
34
Telomerase Activation and ATRX Mutations Are Independent Risk Factors for Metastatic Pheochromocytoma and Paraganglioma. ( 30301828 )
2019
35
Retroperitoneal paraganglioma: a chameleon masquerading as an adrenal pheochromocytoma. ( 30371110 )
2019
36
Regarding: A clinical prediction model to estimate the metastatic potential of pheochromocytoma/paraganglioma: ASES score. ( 30409407 )
2019
37
Molecular Profiling of Pheochromocytoma and Abdominal Paraganglioma Stratified by the PASS Algorithm Reveals Chromogranin B as Associated With Histologic Prediction of Malignant Behavior. ( 30451732 )
2019
38
Pheochromocytoma and paraganglioma-an update on diagnosis, evaluation, and management. ( 30603807 )
2019
39
68Ga-DOTATOC PET/CT in the localization of metastatic extra-adrenal paraganglioma and pheochromocytoma compared with 18F-DOPA PET/CT. ( 30630744 )
2019
40
Reply to letter to editor regarding: "A clinical prediction model to estimate the metastatic potential of Pheochromocytoma/paraganglioma: ASES score". ( 30686514 )
2019
41
Positive Impact of Genetic Test on the Management and Outcome of Patients With Paraganglioma and/or Pheochromocytoma. ( 30698717 )
2019
42
Efficacy and Safety of Ablative Therapy in the Treatment of Patients with Metastatic Pheochromocytoma and Paraganglioma. ( 30736463 )
2019
43
Clinical profiles of patients with surgically resected pheochromocytoma and paraganglioma. ( 30808127 )
2019
44
DOGMA IS MADE TO BE BROKEN. WHY ARE WE POSTPONING CURATIVE SURGERY TO ADMINISTER INEFFECTIVE ALPHA ADRENORECEPTOR BLOCKADE IN MOST PATIENTS UNDERGOING PHEOCHROMOCYTOMA REMOVAL? ( 30817194 )
2019
45
A NECESSITY, NOT A SECOND THOUGHT: PRE-OPERATIVE ALPHA-ADRENOCEPTOR BLOCKADE IN PHEOCHROMOCYTOMA PATIENTS. ( 30817195 )
2019
46
Severe hemodynamic instability during elective surgery for a patient with a giant pheochromocytoma: A case report. ( 30831508 )
2019
47
The Investigation into the Toxic Potential of Iron Oxide Nanoparticles Utilizing Rat Pheochromocytoma and Human Neural Stem Cells. ( 30889833 )
2019
48
Bidirectional ventricular tachycardia in ACTH-producing pheochromocytoma. ( 30897623 )
2019
49
Pheochromocytoma triggers takotsubo syndrome. ( 30903176 )
2019
50
Pheochromocytoma: 20 years of improving surgical care. ( 30922520 )
2019

Variations for Adrenal Gland Pheochromocytoma

Cosmic variations for Adrenal Gland Pheochromocytoma:

9 (show top 50) (show all 62)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM100047 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.389T>G p.V130G 3:10146562-10146562 0
2 COSM14283 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.491A>G p.Q164R 3:10149814-10149814 0
3 COSM17662 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.492G>T p.Q164H 3:10149815-10149815 0
4 COSM18097 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.482G>A p.R161Q 3:10149805-10149805 0
5 COSM14311 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.499C>T p.R167W 3:10149822-10149822 0
6 COSM14321 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.227T>A p.F76Y 3:10142074-10142074 0
7 COSM5885100 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.250G>A p.V84M 3:10142097-10142097 0
8 COSM6444479 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.260T>C p.V87A 3:10142107-10142107 0
9 COSM144975 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.475A>G p.K159E 3:10149798-10149798 0
10 COSM17982 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.496G>T p.V166F 3:10149819-10149819 0
11 COSM236660 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.250G>C p.V84L 3:10142097-10142097 0
12 COSM17666 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.593T>C p.L198P 3:10149916-10149916 0
13 COSM10662 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.743G>A p.R248Q 17:7674220-7674220 0
14 COSM44914 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.349G>C p.G117R 17:7676020-7676020 0
15 COSM43678 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.305C>T p.T102I 17:7676064-7676064 0
16 COSM966 RET adrenal gland,adrenal gland,pheochromocytoma,NS c.1900T>C p.C634R 10:43114500-43114500 0
17 COSM965 RET adrenal gland,adrenal gland,pheochromocytoma,NS c.2753T>C p.M918T 10:43121968-43121968 0
18 COSM220089 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1885G>A p.Q616fs*4 17:31225134-31225134 0
19 COSM329092 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1721+3A>T p.A548fs*13 17:31221932-31221932 0
20 COSM30670 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.7646C>G p.S2549* 17:31356490-31356490 0
21 COSM329090 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.226G>T p.E76* 17:31159031-31159031 0
22 COSM5885098 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.5665G>T p.E1889* 17:31330351-31330351 0
23 COSM329093 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1722-1G>A p.? 17:31223443-31223443 0
24 COSM330587 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.205-1G>C p.R69Xfs*7 17:31159009-31159009 0
25 COSM327926 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.3158C>A p.S1053* 17:31230886-31230886 0
26 COSM327927 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.7582C>T p.Q2528* 17:31352381-31352381 0
27 COSM33676 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.6855C>A p.Y2285* 17:31338739-31338739 0
28 COSM329087 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.4558C>T p.Q1520* 17:31260496-31260496 0
29 COSM1710108 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.7300C>T p.Q2434* 17:31349230-31349230 0
30 COSM24441 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.3721C>T p.R1241* 17:31235623-31235623 0
31 COSM330588 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.2409+1G>A p.A776_Q803del 17:31227607-31227607 0
32 COSM329089 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1466A>G p.Y489C 17:31214524-31214524 0
33 COSM707 MET adrenal gland,adrenal gland,pheochromocytoma,NS c.3029C>T p.T1010I 7:116771936-116771936 0
34 COSM5967149 MET adrenal gland,adrenal gland,pheochromocytoma,NS c.607T>A p.S203T 7:116699691-116699691 0
35 COSM5946188 MET adrenal gland,adrenal gland,pheochromocytoma,NS c.352A>T p.M118L 7:116699436-116699436 0
36 COSM5945782 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.7393G>A p.G2465S 12:49039461-49039461 0
37 COSM6342201 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.6797T>C p.F2266S 12:49040163-49040163 0
38 COSM144597 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.7019T>C p.L2340P 12:49039941-49039941 0
39 COSM5945788 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.7954C>T p.R2652W 12:49038592-49038592 0
40 COSM5945789 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.14856C>A p.N4952K 12:49026300-49026300 0
41 COSM5945787 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.11854C>G p.L3952V 12:49032041-49032041 0
42 COSM5945783 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.14858A>G p.N4953S 12:49026298-49026298 0
43 COSM499 HRAS adrenal gland,adrenal gland,pheochromocytoma,NS c.182A>G p.Q61R 11:533874-533874 0
44 COSM496 HRAS adrenal gland,adrenal gland,pheochromocytoma,NS c.181C>A p.Q61K 11:533875-533875 0
45 COSM486 HRAS adrenal gland,adrenal gland,pheochromocytoma,NS c.37G>C p.G13R 11:534286-534286 0
46 COSM1732355 H3F3A adrenal gland,adrenal gland,pheochromocytoma,NS c.103G>T p.G35W 1:226064454-226064454 0
47 COSM27887 GNAS adrenal gland,adrenal gland,pheochromocytoma,NS c.601C>T p.R201C 20:58909365-58909365 0
48 COSM19176 FGFR1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1638C>A p.N546K 8:38417331-38417331 0
49 COSM6188660 EPAS1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1592C>T p.P531L 2:46380264-46380264 0
50 COSM6995498 EPAS1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1588G>C p.A530P 2:46380260-46380260 0

Expression for Adrenal Gland Pheochromocytoma

Search GEO for disease gene expression data for Adrenal Gland Pheochromocytoma.

Pathways for Adrenal Gland Pheochromocytoma

Pathways related to Adrenal Gland Pheochromocytoma according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.51 MTOR SOCS3 STAT3
2
Show member pathways
12.46 MTOR NOS3 STAT3
3
Show member pathways
12.33 MTOR SOCS3 STAT3
4
Show member pathways
12.31 NOS3 SOCS3 STAT3
5
Show member pathways
12.11 MTOR SOCS3 STAT3
6
Show member pathways
12.05 MTOR SOCS3 STAT3
7
Show member pathways
11.91 MTOR NOS3 SOCS3 STAT3
8
Show member pathways
11.89 MTOR SOCS3 STAT3
9 11.79 MTOR NOS3 STAT3
10 11.54 MTOR STAT3
11 11.5 MTOR NOS3 STAT3
12 11.49 MTOR SOCS3 STAT3
13 11.48 MTOR STAT3
14 11.46 NOS3 STAT3
15 11.44 MTOR SOCS3
16 11.42 BNIP3 MTOR
17
Show member pathways
11.39 SOCS3 STAT3
19 11.31 SOCS3 STAT3
20 11.27 MTOR STAT3
21 11.27 MTOR SOCS3 STAT3
22
Show member pathways
11.23 BNIP3 STAT3
23 11.23 SOCS3 STAT3
24
Show member pathways
11.19 SOCS3 STAT3
25 11.16 SOCS3 STAT3
26 11.09 SOCS3 STAT3
27 11.05 SOCS3 STAT3
28
Show member pathways
11 SOCS3 STAT3
29 10.99 MTOR NOS3
30
Show member pathways
10.97 MTOR NOS3 SOCS3 STAT3
31
Show member pathways
10.94 SOCS3 STAT3
32 10.87 MTOR SOCS3 STAT3
33 10.71 SOCS3 STAT3

GO Terms for Adrenal Gland Pheochromocytoma

Biological processes related to Adrenal Gland Pheochromocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.58 MTOR NOS3 STAT3
2 negative regulation of cell death GO:0060548 9.46 BNIP3 STAT3
3 negative regulation of apoptotic process GO:0043066 9.46 ANXA5 BNIP3 SOCS3 STAT3
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.43 SOCS3 STAT3
5 regulation of protein phosphorylation GO:0001932 9.37 MTOR SOCS3
6 cardiac muscle contraction GO:0060048 9.32 KCNH2 MTOR
7 JAK-STAT cascade GO:0007259 9.26 SOCS3 STAT3
8 interleukin-6-mediated signaling pathway GO:0070102 8.96 SOCS3 STAT3
9 regulation of mitochondrial membrane permeability GO:0046902 8.62 BNIP3 STAT3

Molecular functions related to Adrenal Gland Pheochromocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 scaffold protein binding GO:0097110 8.96 KCNH2 NOS3
2 identical protein binding GO:0042802 8.92 BNIP3 KCNH2 MTOR STAT3

Sources for Adrenal Gland Pheochromocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....